Rettenmaier MA, et al. - Given the varying success rate of hyperthermic intraperitoneal chemotherapy (HIPEC), intraperitoneal chemotherapy (IP) and dose-dense (DD) chemotherapy in the treatment of advanced-stage ovarian carcinoma, researchers here sought to compare the clinical benefits associated with these specific forms of chemotherapy administration. They retrospectively assessed advanced-stage ovarian cancer patients who were managed with platinum/taxane chemotherapy via a DD regimen (n = 100), IP approach (n = 81) or a DD regimen in conjunction with HIPEC (n = 64). Outcomes revealed that treatment with HIPEC and IP chemotherapy provided progression-free survival advantages to the ovarian cancer patients compared with DD chemotherapy. However, they identified no overall survival advantage related to the chemotherapy regimens; this may be due to the retrospective nature of the study or differing time periods wherein the specific patient cohorts underwent treatment.